Tarsus Pharmaceuticals Appoints Dr. Elizabeth Yeu as Chief Medical Officer

Tarsus Pharmaceuticals has announced the appointment of Elizabeth Yeu, MD, as Chief Medical Officer, effective November 4, 2024. Dr. Yeu, an esteemed ophthalmologist with over two decades of clinical and leadership experience, will lead the company’s medical organization and oversee key areas including medical affairs, pharmacovigilance, evidence generation, and patient safety.

Dr. Yeu’s Expanded Role at Tarsus

Having served as Tarsus’ Chief Medical Advisor since 2020 and a board member since 2021, Dr. Yeu’s transition to Chief Medical Officer positions her to shape the company’s medical strategy and execution. She will report directly to Tarsus CEO and Chairman, Bobby Azamian, MD, PhD, and will step down from her board role as she joins the executive team.

“Liz has been an invaluable partner and advisor to Tarsus, and we are thrilled to apply her medical expertise and leadership directly to enhancing the impact of our medical organization as we continue to propel the XDEMVY launch,” said Dr. Azamian. “Her unique clinical perspective will be critical to our continued success and leadership in eye care and beyond, as we advance other meaningful pipeline programs addressing areas of significant unmet need.”

Commitment to Clinical Excellence and Patient Care

Dr. Yeu expressed her enthusiasm for this new role and the opportunity to deepen her contribution to Tarsus’ mission.

“I’m fortunate to have been a part of the Tarsus journey since the early days and am delighted for the opportunity to work even more closely with such a talented and passionate team,” Dr. Yeu said. “I look forward to contributing full time to the company’s efforts to deliver novel therapies, such as XDEMVY, to more patients and ensuring my fellow clinicians have the evidence and information they need to provide optimal care to their patients.”

Accomplished Career and Leadership in Ophthalmology

Dr. Yeu is a practicing ophthalmologist and partner at Virginia Eye Consultants, where she will continue her clinical practice alongside her role at Tarsus. With hundreds of publications and numerous speaking engagements on topics such as refractive cataract surgery and ocular disease management, she is widely recognized as a thought leader in eye care.

Dr. Yeu’s influence extends across multiple prestigious boards and committees:

     • American Board of Ophthalmology: Examiner

     • American Academy of Ophthalmology (AAO): Chair of the refractive surgery section for the annual meeting

     • American Society of Cataract and Refractive Surgery (ASCRS): Immediate Past President

She also serves on the boards of STAAR Surgical, the Virginia Eye Foundation, and CVP Physicians, Mid Atlantic.

Education and Continued Dedication to Ophthalmic Training

Dr. Yeu earned her medical degree through an honors program at the University of Florida College of Medicine, completed her ophthalmology residency at Rush University Medical Center as Chief Resident, and pursued a fellowship in cornea, anterior segment, and refractive surgery at Baylor College of Medicine’s Cullen Eye Institute. Dr. Yeu continues to train residents as an Assistant Professor of Ophthalmology at Eastern Virginia Medical School.

Dr. Yeu’s appointment as Chief Medical Officer at Tarsus Pharmaceuticals highlights the company’s dedication to advancing innovative treatments in eye care and ensuring high standards in clinical strategy, medical education, and patient support.